Texas Retina’s Ashkan Abbey, MD, recently participated in a roundtable discussion on “Navigating Wet AMD and DME Using Newer Therapies” available on Eyetube.
Dr. Abbey and fellow panelist Scott Walter, MD, MSc, from Retina Consultants PC in Hartford, Connecticut, sat down with moderator Ferhina Ali, MD, of New York Medical College, to review how they approach wet age-related macular degeneration (AMD) and diabetic macular edema (DME) given the recently expanded menu of treatment options.
The group talked about the role of combination therapy, including vascular endothelial growth factor (VEGF) inhibitors, angiopoietin-2 (Ang-2) inhibitors and steroids, in caring for patients with these conditions. Dr. Abbey highlighted the goal of maintaining patients’ visual acuity and anatomic stability while aiming to extend the time between injections and office visits office visits to reduce the treatment burden. He also discussed potential new wet AMD treatments currently being investigated, including tyrosine kinase inhibitors (TKIs) and gene therapies, along with the possibility of remote monitoring through home ocular coherence tomography (OCT) devices currently under development.
Click here to view the full roundtable discussion.
Eyetube was created to educate ophthalmologists around the world through online video sharing.
Dr. Abbey serves as Texas Retina’s Director of Clinical Research for Dallas and cares for patients in our Dallas Main and Rockwall offices. You can learn more about him here.